SUNWAY CITY, June 13 — Sunway Healthcare Group has signed a groundbreaking Memorandum of Understanding (MoU) with AstraZeneca, marking the first collaboration between a Malaysian private healthcare group and a global pharmaceutical company. The partnership aims to improve healthcare access and delivery through clinical trials, research, and innovative solutions. The MoU was signed by Dr. Khoo Chow Huat of Sunway Healthcare Group and Vinod Narayanan of AstraZeneca Malaysia at the Sunway Sanctuary, witnessed by Dato’ Lau Beng Long and Sylvia Varela.
This collaboration will focus on early screening for lung cancer and integrating the Kidney Failure Risk Equation into lab reports for better management of chronic kidney disease. The partnership also aims to advance clinical research by conducting trials, observational studies, and real-world evidence generation. AstraZeneca will explore Sunway Medical Centre as a site for future Phase I clinical trials, expanding patient access to innovative treatments. Dr. Khoo emphasized the importance of developing solutions for non-communicable diseases, while Vinod highlighted the potential of leveraging AI and digital technologies to accelerate medical advancements.
